KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Non Operating Investment Income (2021 - 2022)

Xenon Pharmaceuticals (XENE) has disclosed Non Operating Investment Income for 2 consecutive years, with -$1.3 million as the latest value for Q2 2022.

  • On a quarterly basis, Non Operating Investment Income fell 7055.56% to -$1.3 million in Q2 2022 year-over-year; TTM through Jun 2022 was -$4.7 million, a N/A change, with the full-year FY2021 number at -$719000.0, down 18075.0% from a year prior.
  • Non Operating Investment Income was -$1.3 million for Q2 2022 at Xenon Pharmaceuticals, up from -$3.4 million in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of -$18000.0 in Q2 2021 to a low of -$3.4 million in Q1 2022.